Global Glucagon Like Peptide 2 Receptor Market Size By Type (FE-20399, Glepaglutide), By Application (Short Bowel Syndrome, Diabetes), By Region, And Segment Forecasts, 2023 to 2032

The Global Glucagon Like Peptide 2 (GLP-2) Receptor Market was valued at USD 1.1 billion in 2023 and is projected to surpass USD 2.9 billion by 2031, growing at a CAGR of 13.1% during the forecast period from 2023 to 2031. This market is witnessing robust growth due to increasing prevalence of gastrointestinal disorders such as short bowel syndrome (SBS) and Crohn’s disease, rising awareness of GLP-2 based therapies, and the expansion of clinical research on gut-healing therapeutics.

GLP-2 receptor agonists are a key innovation in enteric health and gastrointestinal treatment. They promote intestinal growth, improve nutrient absorption, and reduce the dependency on parenteral nutrition in patients with SBS, making them a vital advancement in digestive disease management.

Drivers:

1. Rising Prevalence of Short Bowel Syndrome and Intestinal Failure: The growing incidence of SBS and related conditions globally is a significant driver for the GLP-2 receptor market. The need for targeted, effective, and long-term treatment options is pushing demand for GLP-2 receptor-based therapies.

2. Advances in Gastrointestinal Drug Discovery: Pharmaceutical R&D is increasingly focusing on peptide-based therapies. Technological advancements have improved drug delivery methods and molecular engineering, enhancing the efficacy of GLP-2 receptor agonists.

3. Increasing Regulatory Approvals and Orphan Drug Designations: GLP-2 receptor agonists like teduglutide have gained regulatory traction, with several approvals in major markets. The orphan drug status granted by agencies such as the FDA and EMA provides incentives for market expansion.

Restraints:

1. High Cost of Treatment: The significant cost associated with GLP-2 therapies limits access, particularly in developing markets. These treatments often require long-term administration and may not be covered under standard insurance plans.

2. Limited Patient Pool: Despite the clinical effectiveness of GLP-2 receptor therapies, their target applications are relatively rare diseases, which can limit the market size in the absence of expanded indications.

Opportunity:

1. Expansion of Indications Beyond SBS: Ongoing clinical trials are evaluating the role of GLP-2 receptor agonists in broader gastrointestinal applications such as inflammatory bowel disease (IBD) and chemotherapy-induced mucositis. This represents a significant opportunity for market expansion.

2. Emerging Markets and Global Access Programs: With increasing awareness and healthcare reforms, emerging markets are becoming important for pharmaceutical penetration. Government initiatives and global health programs are creating new pathways for access to GLP-2 therapies.

Market by System Type Insights:

By system type, Injectable GLP-2 Receptor Agonists dominated the market in 2023 due to the established efficacy of subcutaneous administration. This route enables accurate dosage and improved bioavailability. However, research is ongoing into oral formulations, which may revolutionize the delivery landscape in the coming years by enhancing patient compliance.

Market by End-use Insights:

The Hospital and Specialty Clinics segment held the largest market share in 2023. These institutions are primary centers for the diagnosis and management of SBS and related conditions, often housing the specialized staff and infrastructure required for GLP-2 therapy administration. The homecare settings segment is expected to grow steadily due to patient preference for convenient, at-home administration supported by self-injection devices.

Market by Regional Insights:

North America led the market in 2023, driven by strong healthcare infrastructure, early adoption of advanced therapeutics, and favorable reimbursement frameworks. Europe followed, benefitting from orphan drug initiatives and advanced research collaborations. The Asia-Pacific region is forecasted to grow at the highest CAGR, fueled by rising healthcare awareness, increased investment in biotech R&D, and expanding diagnosis of rare gastrointestinal conditions.

Competitive Scenario:

Key companies in the Global Glucagon Like Peptide 2 Receptor Market include:

Takeda Pharmaceutical Company Limited

Zealand Pharma A/S

Hanmi Pharmaceutical Co., Ltd.

Ironwood Pharmaceuticals, Inc.

Nestlé Health Science

Theravance Biopharma

Novo Nordisk A/S

These players are focusing on developing novel analogues, expanding indications, securing regulatory designations, and engaging in strategic collaborations to enhance their market presence.

Key Market Developments:

2023: Takeda expanded its GLP-2 agonist indications with new clinical trial results targeting Crohn’s disease-related intestinal damage.

2024: Zealand Pharma received EMA fast-track designation for its next-generation GLP-2 receptor modulator.

2025: Nestlé Health Science announced a licensing agreement with a biotech firm to develop oral GLP-2 agonists for pediatric SBS treatment.

Scope of Work – Global Glucagon Like Peptide 2 Receptor Market

Report Metric Details

Market Size (2023) USD 1.1 billion

Projected Market Size (2031) USD 2.9 billion

CAGR (2023–2031) 13.1%

Market Segments By System Type (Injectable, Oral), By End-use (Hospitals, Clinics, Homecare)

Growth Drivers Rising SBS prevalence, orphan drug approvals, pharmaceutical R&D advancements

Opportunities Expanded indications, emerging market access, oral formulation development

FAQs:

1) What is the current market size of the Global Glucagon Like Peptide 2 Receptor Market?

The market was valued at USD 1.1 billion in 2023.

2) What is the major growth driver of the Global Glucagon Like Peptide 2 Receptor Market?

The major growth driver is the rising prevalence of short bowel syndrome and increased adoption of GLP-2 based therapies.

3) Which is the largest region during the forecast period in the Global Glucagon Like Peptide 2 Receptor Market?

North America held the largest market share in 2023, with Asia-Pacific projected to grow fastest.

4) Which segment accounted for the largest market share in the Global Glucagon Like Peptide 2 Receptor Market?

The Injectable GLP-2 Receptor Agonists segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Glucagon Like Peptide 2 Receptor Market?

Key players include Takeda, Zealand Pharma, Hanmi Pharmaceutical, Ironwood, Nestlé Health Science, and Theravance Biopharma.